Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconsidering the spectral distribution of light: Do people perceive watts or photons?

Lighting research & technology (London, England : 2001)·2024
Same author

[Ultrawide-field fundus photography showing frosted branch angiitis].

Journal francais d'ophtalmologie·2024
Same author

[Central serous chorioretinopathy: A review].

Journal francais d'ophtalmologie·2023
Same author

[Post-traumatic stress disorder, depression and anxiety in parents of children with epilepsy].

L'Encephale·2021
Same author

[Metacognitive deficit in schizophrenia: Characteristics and links].

L'Encephale·2021
Same author

[Effects of continuous positive airway pressure on depression, anxiety and quality of life in obstructive sleep apnea hypopnea syndrome patients].

L'Encephale·2021

Related Experiment Video

Updated: Jun 13, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Protein delivery for retinal diseases: from basic considerations to clinical applications.

M El Sanharawi1, L Kowalczuk, E Touchard

  • 1Inserm, UMRS 872, Centre de Recherche des Cordeliers, Paris, France.

Progress in Retinal and Eye Research
|April 20, 2010
PubMed
Summary

Direct intravitreous injections of therapeutic proteins offer targeted treatment for retinal diseases like wet age-related macular degeneration (AMD). Further research into protein delivery is needed to optimize efficacy and develop advanced ocular drug delivery systems.

More Related Videos

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Related Experiment Videos

Last Updated: Jun 13, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Area of Science:

  • Ophthalmology
  • Biotechnology
  • Drug Delivery

Background:

  • The eye's unique structure allows for targeted protein therapies, with intravitreous injections being a safe and effective method.
  • Ranibizumab, an anti-VEGF antibody fragment (Fab), is a standard treatment for wet age-related macular degeneration (AMD), proving the concept of protein administration in the vitreous.
  • Various biomolecules, including antibodies, peptides, and growth factors, show therapeutic potential in animal models for ocular diseases.

Purpose of the Study:

  • To review current knowledge on protein delivery for treating eye diseases.
  • To explore novel non-viral gene therapy technologies for ocular drug delivery.
  • To identify areas for optimizing treatment regimens and enhancing the efficacy of protein-based therapies.

Main Methods:

  • Review of existing literature on protein pharmacokinetics within the eye.
  • Analysis of current therapeutic protein applications in ophthalmology.
  • Exploration of emerging non-viral gene therapy technologies for ocular drug delivery.

Main Results:

  • Intravitreous protein administration is feasible and effective for retinal diseases.
  • Understanding protein penetration, distribution, elimination, and metabolism is crucial for optimizing delivery.
  • Novel drug delivery systems are needed for controlled and sustained release of therapeutic proteins.

Conclusions:

  • Protein-based therapies hold significant promise for treating ocular diseases.
  • Further research into ocular pharmacokinetics and advanced drug delivery systems is essential.
  • Non-viral gene therapy presents a promising avenue for future ocular treatment strategies.